Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A pharmaceutical formulation comprising: (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125μm and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation.

2. (Currently Amended) ~~A~~ The pharmaceutical formulation as claimed in claim 1 wherein the microcrystalline cellulose has a mean particle size less than or equal to 100μm.

3. (Currently Amended) ~~A~~ The pharmaceutical formulation as claimed in ~~claim 1 or~~ claim 2 wherein the ratio of microcrystalline cellulose:pregelatinised starch is in the range of 2:1 to 15:1.

4. (Currently Amended) ~~A~~ The pharmaceutical composition as claimed in ~~any one of claims 1-3~~ claim 3 wherein the microcrystalline cellulose and pregelatinised starch comprise water which is present in an amount 3-6% w/w based on the total weight of the formulation.

5. (Currently Amended) ~~A~~ The pharmaceutical formulation as claimed in ~~any one of claims 1-4~~ claim 1 wherein the levothyroxine sodium is hydrated.

6. (Currently Amended) ~~A~~ The pharmaceutical formulation as claimed in claim 5 wherein the levothyroxine sodium is the pentahydrate form.

7. (Currently Amended) ~~A~~ The pharmaceutical formulation as claimed in ~~any one of claims 1-6~~ claim 1 which further comprises one or more glidant/lubricants.

8. (Currently Amended) ~~A~~ The pharmaceutical formulation as claimed in claim 7 wherein the glidant/lubricants are selected from the group consisting of colloidal anhydrous silica, talc, ~~and/or~~ magnesium stearate, and mixtures thereof.

9. (Currently Amended) ~~A~~ The pharmaceutical formulation as claimed in ~~any one of claims 1-8~~ claim 1 which is stable to the extent that potency decreases by less than 5% when the pharmaceutical formulation is stored at 25°C and 60% relative humidity for 12 months.

10. (Currently Amended) ~~A~~ The pharmaceutical formulation as claimed in ~~any of claims 1-9~~ claim 1 in unit dose form.

11. (Currently Amended) ~~A~~ The pharmaceutical formulation as claimed in claim 10 wherein the unit dose form is a tablet.

12. (Cancelled).

13. (Cancelled).

14. (Cancelled).

15. (Currently Amended) A method of treating thyroid hormone disorders comprising administering a pharmaceutical formulation as claimed in ~~any of claims 1-11~~ claim 1 to a mammal.

16. (Currently Amended) A process for preparing a pharmaceutical formulation as claimed in ~~any of claims 1-11~~ claim 1 comprising (a) preparing a triturate of levothyroxine sodium, (b) mixing the triturate with the remaining components of the pharmaceutical formulation, and (c) compression.

17. (New) The method of claim 15 wherein said mammal is a human.